Mutual of America Capital Management LLC Sells 2,945 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mutual of America Capital Management LLC trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 81,729 shares of the medical equipment provider’s stock after selling 2,945 shares during the period. Mutual of America Capital Management LLC owned 0.12% of Lantheus worth $6,562,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. UMB Bank n.a. raised its position in Lantheus by 161.4% in the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. GAMMA Investing LLC raised its holdings in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares during the last quarter. Principal Securities Inc. bought a new position in Lantheus in the 4th quarter valued at approximately $28,000. Fidelis Capital Partners LLC acquired a new stake in Lantheus during the 1st quarter worth approximately $34,000. Finally, FinTrust Capital Advisors LLC grew its holdings in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 232 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Lantheus stock opened at $108.56 on Friday. The stock has a market capitalization of $7.52 billion, a price-to-earnings ratio of 16.57 and a beta of 0.50. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The stock’s 50 day moving average price is $105.78 and its two-hundred day moving average price is $83.79.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period last year, the firm posted $1.40 earnings per share. On average, equities analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Analyst Ratings Changes

LNTH has been the topic of a number of recent research reports. B. Riley lifted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. JMP Securities lowered their price objective on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Leerink Partners lifted their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Finally, Truist Financial decreased their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Insider Buying and Selling at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now owns 62,216 shares in the company, valued at approximately $7,661,900.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,852 shares of company stock valued at $3,922,001. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.